Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review

Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Vozmediano-Chicharro R [verfasserIn] Blasco Hernández P [verfasserIn] Madurga-Patuel B [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin.

Übergeordnetes Werk:	In: Research and Reports in Urology - Dove Medical Press, 2012, (2020), Seite 321-330
Übergeordnetes Werk:	year:2020 ; pages:321-330

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ040877051

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ040877051
003	DE-627
005	20230308042108.0
007	cr uuu---uuuuu
008	230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ040877051
035			\|a (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC870-923
100	0		\|a Vozmediano-Chicharro R \|e verfasserin \|4 aut
245	1	0	\|a Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin
650		4	\|a antimuscarinics
650		4	\|a frequency
650		4	\|a urgency
650		4	\|a overactive bladder
650		4	\|a oxybutynin
650		4	\|a transdermal oxybutynin.
653		0	\|a Diseases of the genitourinary system. Urology
700	0		\|a Blasco Hernández P \|e verfasserin \|4 aut
700	0		\|a Madurga-Patuel B \|e verfasserin \|4 aut
773	0	8	\|i In \|t Research and Reports in Urology \|d Dove Medical Press, 2012 \|g (2020), Seite 321-330 \|w (DE-627)684967898 \|w (DE-600)2649530-2 \|x 22532447 \|7 nnns
773	1	8	\|g year:2020 \|g pages:321-330
856	4	0	\|u https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2253-2447 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2020 \|h 321-330

Indexfelder

author_variant	v c r vcr b h p bhp m p b mpb
matchkey_str	article:22532447:2020----::nihsnohmngmnooeatvbadrihrndraoy
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a DE-627 ger DE-627 rakwb eng RC870-923 Vozmediano-Chicharro R verfasserin aut Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology Blasco Hernández P verfasserin aut Madurga-Patuel B verfasserin aut In Research and Reports in Urology Dove Medical Press, 2012 (2020), Seite 321-330 (DE-627)684967898 (DE-600)2649530-2 22532447 nnns year:2020 pages:321-330 https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a kostenfrei https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU kostenfrei https://doaj.org/toc/2253-2447 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 321-330
spelling	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a DE-627 ger DE-627 rakwb eng RC870-923 Vozmediano-Chicharro R verfasserin aut Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology Blasco Hernández P verfasserin aut Madurga-Patuel B verfasserin aut In Research and Reports in Urology Dove Medical Press, 2012 (2020), Seite 321-330 (DE-627)684967898 (DE-600)2649530-2 22532447 nnns year:2020 pages:321-330 https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a kostenfrei https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU kostenfrei https://doaj.org/toc/2253-2447 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 321-330
allfields_unstemmed	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a DE-627 ger DE-627 rakwb eng RC870-923 Vozmediano-Chicharro R verfasserin aut Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology Blasco Hernández P verfasserin aut Madurga-Patuel B verfasserin aut In Research and Reports in Urology Dove Medical Press, 2012 (2020), Seite 321-330 (DE-627)684967898 (DE-600)2649530-2 22532447 nnns year:2020 pages:321-330 https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a kostenfrei https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU kostenfrei https://doaj.org/toc/2253-2447 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 321-330
allfieldsGer	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a DE-627 ger DE-627 rakwb eng RC870-923 Vozmediano-Chicharro R verfasserin aut Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology Blasco Hernández P verfasserin aut Madurga-Patuel B verfasserin aut In Research and Reports in Urology Dove Medical Press, 2012 (2020), Seite 321-330 (DE-627)684967898 (DE-600)2649530-2 22532447 nnns year:2020 pages:321-330 https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a kostenfrei https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU kostenfrei https://doaj.org/toc/2253-2447 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 321-330
allfieldsSound	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a DE-627 ger DE-627 rakwb eng RC870-923 Vozmediano-Chicharro R verfasserin aut Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology Blasco Hernández P verfasserin aut Madurga-Patuel B verfasserin aut In Research and Reports in Urology Dove Medical Press, 2012 (2020), Seite 321-330 (DE-627)684967898 (DE-600)2649530-2 22532447 nnns year:2020 pages:321-330 https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a kostenfrei https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU kostenfrei https://doaj.org/toc/2253-2447 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 321-330
language	English
source	In Research and Reports in Urology (2020), Seite 321-330 year:2020 pages:321-330
sourceStr	In Research and Reports in Urology (2020), Seite 321-330 year:2020 pages:321-330
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin. Diseases of the genitourinary system. Urology
isfreeaccess_bool	true
container_title	Research and Reports in Urology
authorswithroles_txt_mv	Vozmediano-Chicharro R @@aut@@ Blasco Hernández P @@aut@@ Madurga-Patuel B @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	684967898
id	DOAJ040877051
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ040877051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308042108.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ040877051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vozmediano-Chicharro R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ra&uacute;l Vozmediano-Chicharro,1 Pedro Blasco Hern&aacute;ndez,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de M&aacute;laga, M&aacute;laga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, C&aacute;diz, SpainCorrespondence: Ra&uacute;l Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de M&aacute;laga, Av. de Carlos Haya, 84, M&aacute;laga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals&rsquo; lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient&rsquo;s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antimuscarinics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">frequency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">urgency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overactive bladder</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxybutynin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transdermal oxybutynin.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Blasco Hernández P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Madurga-Patuel B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Research and Reports in Urology</subfield><subfield code="d">Dove Medical Press, 2012</subfield><subfield code="g">(2020), Seite 321-330</subfield><subfield code="w">(DE-627)684967898</subfield><subfield code="w">(DE-600)2649530-2</subfield><subfield code="x">22532447</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:321-330</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2253-2447</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">321-330</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Vozmediano-Chicharro R
spellingShingle	Vozmediano-Chicharro R misc RC870-923 misc antimuscarinics misc frequency misc urgency misc overactive bladder misc oxybutynin misc transdermal oxybutynin. misc Diseases of the genitourinary system. Urology Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
authorStr	Vozmediano-Chicharro R
ppnlink_with_tag_str_mv	@@773@@(DE-627)684967898
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC870-923
illustrated	Not Illustrated
issn	22532447
topic_title	RC870-923 Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review antimuscarinics frequency urgency overactive bladder oxybutynin transdermal oxybutynin
topic	misc RC870-923 misc antimuscarinics misc frequency misc urgency misc overactive bladder misc oxybutynin misc transdermal oxybutynin. misc Diseases of the genitourinary system. Urology
topic_unstemmed	misc RC870-923 misc antimuscarinics misc frequency misc urgency misc overactive bladder misc oxybutynin misc transdermal oxybutynin. misc Diseases of the genitourinary system. Urology
topic_browse	misc RC870-923 misc antimuscarinics misc frequency misc urgency misc overactive bladder misc oxybutynin misc transdermal oxybutynin. misc Diseases of the genitourinary system. Urology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Research and Reports in Urology
hierarchy_parent_id	684967898
hierarchy_top_title	Research and Reports in Urology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)684967898 (DE-600)2649530-2
title	Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
ctrlnum	(DE-627)DOAJ040877051 (DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a
title_full	Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
author_sort	Vozmediano-Chicharro R
journal	Research and Reports in Urology
journalStr	Research and Reports in Urology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	321
author_browse	Vozmediano-Chicharro R Blasco Hernández P Madurga-Patuel B
class	RC870-923
format_se	Elektronische Aufsätze
author-letter	Vozmediano-Chicharro R
author2-role	verfasserin
title_sort	insights into the management of overactive bladder with transdermal oxybutynin: a practical review
callnumber	RC870-923
title_auth	Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
abstract	Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin
abstractGer	Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin
abstract_unstemmed	Raúl Vozmediano-Chicharro,1 Pedro Blasco Hernández,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de Málaga, Málaga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, Cádiz, SpainCorrespondence: Raúl Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de Málaga, Av. de Carlos Haya, 84, Málaga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient’s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review
url	https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU https://doaj.org/toc/2253-2447
remote_bool	true
author2	Blasco Hernández P Madurga-Patuel B
author2Str	Blasco Hernández P Madurga-Patuel B
ppnlink	684967898
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC870-923
up_date	2024-07-03T17:14:17.832Z
_version_	1803578882481192960
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ040877051</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308042108.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ040877051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ5654c28a59f74f92be70cc853f51a86a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vozmediano-Chicharro R</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ra&uacute;l Vozmediano-Chicharro,1 Pedro Blasco Hern&aacute;ndez,2 Blanca Madurga-Patuel3 1Service of Urology, Hospital Universitario Carlos Haya, Universidad de M&aacute;laga, M&aacute;laga, Spain; 2Service of Urology, Hospital Universitario de Valme, Sevilla, Spain; 3Service of Urology, Hospital Universitario Puerta del Mar, C&aacute;diz, SpainCorrespondence: Ra&uacute;l Vozmediano-ChicharroHospital Universitario Carlos Haya, Universidad de M&aacute;laga, Av. de Carlos Haya, 84, M&aacute;laga 29010, SpainEmail vozmemsn.comAbstract: Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals&rsquo; lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient&rsquo;s perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.Keywords: antimuscarinics, frequency, urgency, overactive bladder, oxybutynin, transdermal oxybutynin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antimuscarinics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">frequency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">urgency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">overactive bladder</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">oxybutynin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">transdermal oxybutynin.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Blasco Hernández P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Madurga-Patuel B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Research and Reports in Urology</subfield><subfield code="d">Dove Medical Press, 2012</subfield><subfield code="g">(2020), Seite 321-330</subfield><subfield code="w">(DE-627)684967898</subfield><subfield code="w">(DE-600)2649530-2</subfield><subfield code="x">22532447</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:321-330</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/5654c28a59f74f92be70cc853f51a86a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/insights-into-the-management-of-overactive-bladder-with-transdermal-ox-peer-reviewed-article-RRU</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2253-2447</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">321-330</subfield></datafield></record></collection>
score	7.3980217

Nicht das Richtige dabei?

Schreiben Sie uns!

Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?